[1]杨倩,林荣军,刘毅.丙酸氟替卡松和布地奈德福莫特罗吸入治疗儿童轻中度哮喘的效果[J].青岛大学医学院学报,2017,53(03):339-341.[doi:10.13361/j.qdyxy.201703025]
 YANG Qian,LIN Rongjun,LIU Yi.CLINICAL EFFECT OF FLUTICASONE PROPIONATE AEROSOL VERSUS BUDESONIDE/FORMOTEROL IN TREATMENT OF CHILDREN WITH MILD-TO-MODERATE ASTHMA[J].Acta Aacademiae Medicinae Qingdao,2017,53(03):339-341.[doi:10.13361/j.qdyxy.201703025]
点击复制

丙酸氟替卡松和布地奈德福莫特罗吸入治疗儿童轻中度哮喘的效果()
分享到:

《青岛大学医学院学报》[ISSN:1672-4488/CN:37-1356/R]

卷:
第53卷
期数:
2017年03期
页码:
339-341
栏目:
出版日期:
2017-08-07

文章信息/Info

Title:
CLINICAL EFFECT OF FLUTICASONE PROPIONATE AEROSOL VERSUS BUDESONIDE/FORMOTEROL IN TREATMENT OF CHILDREN WITH MILD-TO-MODERATE ASTHMA
文章编号:
1672-4488(2017)03-0339-03
作者:
杨倩1林荣军2刘毅3
青岛大学附属医院儿科,山东 青岛 266071
Author(s):
YANG Qian LIN Rongjun LIU Yi
Department of Paediatrics, The Affiliated Hospital of Qingdao University, Qingdao, 266071, China
关键词:
哮喘丙酸氟替卡松气雾剂布地奈德福莫特罗治疗结果
Keywords:
asthma fluticasone propionate aerosol budesonide formoterol treatment outcome
分类号:
R562.25
DOI:
10.13361/j.qdyxy.201703025
文献标志码:
A
摘要:
目的 观察丙酸氟替卡松气雾剂(辅舒酮)和布地奈德福莫特罗粉吸入剂(信必可都保)治疗儿童轻、中度哮喘的效果及购买控制药物的费用。
方法 选取门诊就诊4~14岁符合轻度、中度哮喘诊断标准并经治疗症状缓解的病儿100例,随机分为两组,各50例,治疗组应用辅舒酮治疗,对照组应用信必可都保治疗。随访治疗1年,观察并比较两组无喘息症状维持时间、急诊就医的次数、治疗前后的最大呼气流量值(PEF值)及购买控制药物的费用。
结果 对照组与治疗组无喘息症状维持时间、急诊就医的次数及治疗前后PEF值比较,差异均无统计学意义(P>0.05);而两组购买控制药物的费用比较差异有显著性(t=-17.57,P<0.05)。
结论 辅舒酮及信必可都保治疗儿童轻、中度哮喘效果无明显差异,但应用辅舒酮治疗费用少于信必可都保。
Abstract:
Objective  To investigate the clinical effect of fluticasone propionate aerosol (Flixotide) versus budesonide/formoterol powder for inhalation (Symbicort Turbuhaler) in the treatment of children with mild-to-moderate asthma, as well as the cost of purchasing controlled drugs.
Methods  A total of 100 children aged 4-14 years who visited the outpatient service, met the diagnostic criteria for mild-to-moderate asthma, and achieved symptom remission after treatment were enrolled and randomly divided into two groups, with 50 children in each group. The children in the treatment group were given Flixotide, and those in the control group were given Symbicort Turbuhaler. All children were followed up for 1 year, and the two groups were compared in terms of the maintenance time of no wheezing symptoms, number of emergency treatments, peak expiratory flow (PEF) before and after treatment, and cost of controlled drugs.
Results  There were no significant differences between the control group and the treatment group in the maintenance time of no wheezing symptoms, number of emergency treatments, and PEF before and after treatment (P>0.05); however, there was a significant difference in the cost of controlled drugs between the two groups (t=-17.57,P<0.05).
Conclusion  There is no significant difference in the clinical effect between Flixotide and Symbicort Turbuhaler in the treatment of children with mild-to-moderate asthma, but Flixotide has a lower cost than Symbicort Turbuhaler.
更新日期/Last Update: 2017-08-13